Oncolytic Viro-Immunotherapy (OVI)
Certain viral infections can lead to the eradication of tumours. This presents the exciting possibility of employing nanoscale viral particles as oncolytic agents. Indeed, thanks to improvements in knowledge regarding viruses and cancers and advances in molecular techniques, it is now possible to engineer viruses with a propensity to selectively target and replicate in cancer cells, thereby destroying them and stimulating the host immune response. This area of ‘oncolytic viro-immunotherapy’ is becoming an increasingly important field of interest, especially in employing biologicals to treat cancer.